Small and Rural
CMS鈥檚 decision in today鈥檚 rule to cut Medicare payments to hospitals for drugs covered under the 340B program will dramatically threaten access to health care for many patients, including uninsured and other vulnerable populations. It is not based on sound policy and punishes hospitals and patients鈥
The AHA welcomes today鈥檚 announcement of a public health emergency for the opioid epidemic and the Administration鈥檚 efforts to enhance access to treatment. This declaration appropriately highlights the urgent need to act so that fewer of our fellow citizens are suffering.
Regulations are essential to ensure safety and accountability. However, the rapid increase in the scope and volume of mandatory requirements diverts resources from the patient-centered mission of health systems, hospitals and post-acute care providers.
鈥
鈥
Over 57 million rural Americans depend on their hospital as an important source of care as well as a critical component of their area's economic and social fabric. Location, size, workforce, payment and access to capital challenge small or rural hospitals and the communities they serve.鈥
The Health Resources and Services Administration has announced that 340B Drug Pricing Program hospitals in areas affected by recent natural disasters can immediately enroll in the program instead of waiting for the normal registration period. 鈥淗RSA recognizes that circumstances surrounding disaster鈥
The House Energy and Commerce Subcommittee on Oversight and Investigations today held a hearing examining how covered entities use the 340B Drug Pricing Program. Established by Congress in 1992, the program mandates that drug manufacturers provide outpatient drugs to eligible health care鈥
As Congress turns to tax reform, a new analysis prepared by Ernst & Young for the AHA finds that hospitals鈥 and health systems鈥 community benefit activities outweigh the value of their federal tax exemption by a factor of 11 to one. According to the report, non-profit hospitals in 2013, the鈥
The latest report from a group financed and backed by the pharmaceutical industry 鈥渃ontinues to misrepresent鈥 the 340B Drug Pricing Program and its 鈥渟uccessful 25-year history of helping hospitals stretch scarce financial resources to expand and improve access to lifesaving prescription drugs and鈥